Novo Nordisk, Wegovy
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) label. This update in the European Union (EU) reflects new data indicating the product’s ability,
Novo’s Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST]
What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy
A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, but analysts remain dubious of the estimate.
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Novo Nordisk A/S NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion, recommending a label update of its blockbuster weekly injection for chronic weight management,
Medscape23h
Semaglutide Bests Liraglutide in Long-Term Weight Loss
Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...
Wegovy, Ozempic may someday be available as monthly injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
STAT8d
Compounded semaglutide is an ill-defined public health crisis
Grappling with obesity and the metabolic diseases cascading from it, they are now among the plurality of Americans who have ...
Everyday Health7d
Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests
A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...
Knowridge6d
Is Wegovy really a gamechanger for heart health? A consultant cardiologist gives his verdict
The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...
Explainer: The side-effects of Ozempic and Wegovy
Is it safe and what are the real risks beyond loose skin and “Ozempic face” – the gaunt ageing effect of drastic weight loss?